Deleted Journal, Год журнала: 2024, Номер unknown
Опубликована: Сен. 30, 2024
Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)
Опубликована: Авг. 28, 2024
Abstract Hyperuricemia, characterized by elevated levels of serum uric acid (SUA), is linked to a spectrum commodities such as gout, cardiovascular diseases, renal disorders, metabolic syndrome, and diabetes, etc. Significantly impairing the quality life for those affected, prevalence hyperuricemia an upward trend globally, especially in most developed countries. UA possesses multifaceted role, antioxidant, pro-oxidative, pro-inflammatory, nitric oxide modulating, anti-aging, immune effects, which are significant both physiological pathological contexts. The equilibrium circulating urate hinges on interplay between production excretion, delicate balance orchestrated transporter functions across various epithelial tissues cell types. While existing research has identified involvement numerous biological processes signaling pathways, precise mechanisms connecting disease etiology remain be fully elucidated. In addition, influence genetic susceptibilities environmental determinants calls detailed nuanced examination. This review compiles data from global epidemiological studies clinical practices, exploring foundations transporters depth. Furthermore, we uncover complex induced inflammation influences individuals with association its relative disease, offering foundation innovative therapeutic approaches advanced pharmacological strategies.
Язык: Английский
Процитировано
75
Drugs, Год журнала: 2023, Номер 83(16), С. 1501 - 1521
Опубликована: Окт. 11, 2023
Язык: Английский
Процитировано
32
Nature Reviews Rheumatology, Год журнала: 2024, Номер 20(4), С. 216 - 231
Опубликована: Март 12, 2024
Язык: Английский
Процитировано
13
Diabetology & Metabolic Syndrome, Год журнала: 2024, Номер 16(1)
Опубликована: Май 12, 2024
Diabetes mellitus is one of the most significant global burden diseases. It well established that a chronic, systemic, low-grade inflammatory condition strongly correlated with type 2 diabetes (T2D) and development target-organ damage (TOD). Sodium-glucose cotransporter inhibitors (SGLTis), novel oral drugs for treatment diabetes, act mainly by reducing glucose reabsorption in proximal renal tubules and/or intestine. Several high-quality clinical trials large observational studies have revealed SGLTis significantly improve cardiovascular outcomes T2D patients. Increasing evidence suggests this closely related to their anti-inflammatory properties, which are manifested reduction plasma concentrations biomarkers. This review analyses potential mechanisms behind effects presents recent therapeutic efficacy treating TOD.
Язык: Английский
Процитировано
10
Biosensors and Bioelectronics, Год журнала: 2024, Номер 261, С. 116509 - 116509
Опубликована: Июнь 20, 2024
Язык: Английский
Процитировано
8
BMJ, Год журнала: 2024, Номер unknown, С. e080035 - e080035
Опубликована: Окт. 30, 2024
To emulate target trials comparing recurrence of nephrolithiasis among patients with pre-existing (overall and stratified by concomitant gout) initiating sodium-glucose cotransporter-2 (SGLT-2) inhibitors versus an active comparator.
Язык: Английский
Процитировано
6
Current Hypertension Reports, Год журнала: 2024, Номер 26(12), С. 463 - 474
Опубликована: Июнь 24, 2024
Purpose of Review Chronic kidney disease and end-stage (ESKD) are well-established risk factors for cardiovascular (CVD), the leading cause mortality in dialysis population. Conventional therapies, such as statins, blood pressure control, renin-angiotensin-aldosterone system blockade, have inadequately addressed this risk, highlighting unmet need effective treatment strategies. Sodium–glucose transporter 2 (SGLT2) inhibitors demonstrated significant renal benefits among patients with type diabetes, heart failure, or CKD at progression. Unfortunately, efficacy data is lacking ESKD was an exclusion criterion all major clinical trials SGLT2 inhibitors. This review explores potential improving outcomes ESKD, focusing on their direct cardiac effects. Recent Findings preclinical studies shown promising application to may provide patients, not only indirectly by preserving remaining function anemia but also directly lowering intracellular sodium calcium levels, reducing inflammation, regulating autophagy, alleviating oxidative stress endoplasmic reticulum within cardiomyocytes endothelial cells. Summary examines current evidence experimental supporting use inhibitors, discusses its safety concerns, outlines ongoing Further research needed evaluate effectiveness inhibitor ESKD.
Язык: Английский
Процитировано
5
Endocrinología Diabetes y Nutrición (English ed ), Год журнала: 2025, Номер 72(1), С. 26 - 36
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Deleted Journal, Год журнала: 2025, Номер unknown
Опубликована: Фев. 21, 2025
Процитировано
0
Annals of Internal Medicine, Год журнала: 2025, Номер unknown
Опубликована: Март 10, 2025
Gout is characterized by deposition of monosodium urate (MSU) crystals in or around joints, tendons, bursae, and other tissues, resulting painful recurrent flares tissue damage. the most common form inflammatory arthritis, with a prevalence 5.1% United States, affecting 12.1 million adults. When levels exceed limit solubility (6.8 mg/dL [400 μmol/L]), MSU may grow. are result responses to crystals. The primary method prevent reduce gout flares, tophi, chronic joint damage below saturation threshold. pathophysiology well understood, inexpensive effective therapies available. However, outcomes for patients remain poorly optimized.
Язык: Английский
Процитировано
0